SS-31 Benefits: What Studies Report

What SS-31 is, as described in published work

SS-31 is a short, mitochondria-targeted tetrapeptide that appears in the literature under the name elamipretide as well as SS-31. A 2025 narrative review in International Journal of Molecular Sciences covered its structure, mechanism of action and therapeutic potential across disease areas (PMID 39940712). Work on the wider chemical family has been published too: a 2022 eLife paper examined structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds, comparing how structural changes altered activity (PMID 35913044).

The point worth holding on to before reading any domain below: the large majority of published SS-31 findings in this citation set come from isolated cells, tissue models or animal disease models. Those are hypothesis-generating settings. They describe what happened in a model system, not what happens in people. Where a finding here is in-vitro or animal, it is labelled as such in the same sentence.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any decisions about health, medication or treatment.

Mechanism: what researchers have reported

The mechanistic framing used most often in this literature is interaction with the inner mitochondrial membrane and its signature phospholipid, cardiolipin. A 2026 study in Journal of Advanced Research investigated restoring cardiolipin homeostasis as a way to mitigate cerebral ischemia-reperfusion injury, reporting suppression of ATG5-mediated neuronal autophagy-dependent ferroptosis in its model (PMID 41831680). The 2022 eLife structure-activity analysis addressed the same compound class from a chemistry angle, asking which features of these mitochondria-targeted tetrapeptides tracked with pharmacological activity (PMID 35913044).

Mechanism is not benefit. A compound can bind a target and change a biochemical readout in a dish without that translating into a meaningful clinical outcome, and the 2025 review that catalogued elamipretide's proposed mechanisms presented therapeutic potential as potential rather than as established clinical benefit (PMID 39940712).

Outcome domains studied

Cardiac injury and ischemia-reperfusion

Heart tissue is one of the most frequently studied settings. A 2025 paper in Biomedicine & Pharmacotherapy tested an SS-31@Fer-1 construct in hypoxia/reoxygenation cardiomyocytes and reported alleviation of ferroptosis through mitochondrial targeting (PMID 39848110). That was a cell-level model of oxygen deprivation and restoration, and the tested agent was a combination construct rather than SS-31 alone, which limits how far the result can be attributed to the peptide by itself. No human cardiac outcome data appears in the verified set summarised here.

Kidney disease

A 2025 review in Cells examined mitochondrial dysfunction as a driver of kidney disease progression and discussed mitochondria-directed strategies within that framework (PMID 40497970). This is a review of a disease mechanism rather than a trial of a compound, so it indicates why researchers have been interested in mitochondrial agents in nephrology, not that any renal benefit has been demonstrated in patients.

Spinal cord injury

A 2023 study in Journal of Neuroinflammation used a traumatic spinal cord injury model and reported that elamipretide alleviated pyroptosis by inhibiting cPLA2-induced lysosomal membrane permeabilization (PMID 36609266). The direction of effect reported was reduction of an inflammatory cell-death pathway in injured tissue. This was preclinical work; it does not describe recovery outcomes in people with spinal cord injury.

Brain injury and cerebral ischemia

A 2024 review in Pharmacological Research addressed the bioenergetics of traumatic brain injury and its long-term impact on brain plasticity and function, situating mitochondrial energy failure as a target of interest after head trauma (PMID 39243913). Separately, the 2026 Journal of Advanced Research cardiolipin study reported reduced neuronal autophagy-dependent ferroptosis in a cerebral ischemia-reperfusion model (PMID 41831680). Together these represent mechanistic and animal-level interest in neuroprotection, not clinical evidence of cognitive or functional recovery.

Genetic mitochondrial and neuromuscular disease

A 2021 paper in Human Molecular Genetics tested SS-31 in a mouse model of Friedreich ataxia and reported efficacy associated with upregulation of frataxin expression (PMID 34387346). This remains one of the more specific mechanistic results in the set, because it linked the peptide to a disease-defining protein deficit. It was nonetheless a rodent study, and rodent efficacy in rare-disease models has historically translated unevenly to human trials.

Tendon and musculoskeletal tissue

A 2022 study in The American Journal of Sports Medicine evaluated SS-31 as a potential strategy for tendinopathy treatment using an in-vitro model (PMID 35862638). The word the researchers used was potential, and the model was cultured cells rather than a tendon in a living athlete. A 2026 review in Sports Medicine assessed safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, a scope that places compounds of this type squarely in the category requiring more evidence (PMID 41966639).

Ocular surface and dry eye

A 2024 paper in Journal of Nanobiotechnology described a comprehensive dry eye therapy approach aimed at overcoming the ocular surface barrier while combating inflammation, oxidation and mitochondrial damage (PMID 38725011). This was a delivery-system and formulation study in a preclinical ocular context, so the reported outcomes concerned the engineered therapy as a whole.

Evidence map

Claims with little or no support in this literature set

Several outcomes commonly attached to SS-31 in general discussion are not supported by the papers summarised here.

• Athletic performance gains. The 2026 Sports Medicine review explicitly framed a portion of the peptide field as unapproved therapies whose safety and efficacy for musculoskeletal injury and athletic performance required evaluation, rather than reporting performance benefits as established (PMID 41966639).
• Fat loss or body composition change. No study in this verified set measured body weight, fat mass or metabolic body composition outcomes; the 2025 review of elamipretide's therapeutic potential is a mechanism-and-indication overview rather than an obesity trial (PMID 39940712).
• Anti-ageing or lifespan extension. The cited work addressed specific injury and disease models, such as the traumatic spinal cord injury model (PMID 36609266), not survival or ageing endpoints.
• Cognitive enhancement in healthy people. The 2024 bioenergetics review concerned traumatic brain injury and its long-term impact on brain plasticity and function, an injury population, not healthy cognition (PMID 39243913).

Dosing information

This page does not list doses. Dose, route and duration figures only carry meaning attached to a specific study population and endpoint, and the verified papers summarised here span cultured cardiomyocytes (PMID 39848110), mouse models (PMID 34387346) and narrative reviews (PMID 39940712), which are not interchangeable. Numbers lifted out of a rodent or in-vitro protocol do not transfer to human use.

Safety and Adverse Events: What Studies Report

The verified set is weighted toward mechanism and efficacy in models rather than human safety surveillance. The 2026 Sports Medicine review is the citation here that directly took safety as an explicit objective, assessing both approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance (PMID 41966639). The 2025 International Journal of Molecular Sciences review covered elamipretide across structure, mechanism and therapeutic potential, the standard format in which tolerability observations are collated secondhand rather than generated (PMID 39940712).

What that means in practice: an absence of adverse events in a cell study such as the tendinopathy in-vitro model (PMID 35862638) is not a safety finding at all, because cultured cells cannot report systemic effects. Readers evaluating risk should treat the human safety picture in this set as incomplete and discuss it with a clinician.

How to read this evidence

1. Check the model. Cells, rodents and reviews answer different questions; the frataxin result came from mice (PMID 34387346).
2. Check what was actually given. Some studies tested combination constructs, as in the SS-31@Fer-1 work (PMID 39848110), so effects cannot be assigned to one component.
3. Check the endpoint. Suppressing a cell-death pathway, as reported in the cerebral ischemia-reperfusion model (PMID 41831680), is a biological readout, not a patient-relevant outcome.
4. Check whether reviews cite primary trials. Reviews such as the kidney mitochondrial dysfunction overview describe a rationale (PMID 40497970).

For background on the compound itself, see the overview at /learn/ss-31/.

References

• Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential (International Journal of Molecular Sciences, 2025)
• Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds (eLife, 2022)
• SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting (Biomedicine & Pharmacotherapy, 2025)
• Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression (Cells, 2025)
• Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization (Journal of Neuroinflammation, 2023)
• Restoring cardiolipin homeostasis mitigates cerebral ischemia-reperfusion injury by suppressing ATG5-mediated neuronal autophagy-dependent ferroptosis (Journal of Advanced Research, 2026)
• The bioenergetics of traumatic brain injury and its long-term impact for brain plasticity and function (Pharmacological Research, 2024)
• SS-31 efficacy in a mouse model of Friedreich ataxia by upregulation of frataxin expression (Human Molecular Genetics, 2021)
• Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model (The American Journal of Sports Medicine, 2022)
• Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage (Journal of Nanobiotechnology, 2024)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)